Aldeyra Therapeutics, Inc (NASDAQ:ALDX) major shareholder Perceptive Advisors Llc purchased 3,200,000 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were acquired at an average price of $4.25 per share, with a total value of $13,600,000.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
ALDX opened at $5.83 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 12.84 and a quick ratio of 12.84. The company has a market capitalization of $173.68 million, a price-to-earnings ratio of -2.93 and a beta of 2.11. The firm’s fifty day moving average price is $4.57 and its two-hundred day moving average price is $4.21. Aldeyra Therapeutics, Inc has a 1 year low of $1.48 and a 1 year high of $8.05.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.14. As a group, equities analysts anticipate that Aldeyra Therapeutics, Inc will post -1.51 EPS for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of ALDX. State Street Corp boosted its holdings in Aldeyra Therapeutics by 4.6% during the 4th quarter. State Street Corp now owns 417,207 shares of the biotechnology company’s stock worth $2,424,000 after acquiring an additional 18,351 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Aldeyra Therapeutics by 7.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 57,647 shares of the biotechnology company’s stock worth $335,000 after buying an additional 4,111 shares during the last quarter. Barclays PLC boosted its holdings in shares of Aldeyra Therapeutics by 104.9% in the 4th quarter. Barclays PLC now owns 22,926 shares of the biotechnology company’s stock worth $133,000 after buying an additional 11,737 shares during the last quarter. Panagora Asset Management Inc. purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter worth about $113,000. Finally, Citigroup Inc. boosted its holdings in shares of Aldeyra Therapeutics by 64.6% in the 4th quarter. Citigroup Inc. now owns 9,298 shares of the biotechnology company’s stock worth $54,000 after buying an additional 3,649 shares during the last quarter. 56.34% of the stock is currently owned by hedge funds and other institutional investors.
About Aldeyra Therapeutics
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Featured Story: What is the strike price in options trading?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.